Compare MGM Resorts International (MGM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Sana Biotechnology Inc — how do they compare? MGM Resorts International trades at $46.57 (market cap $11.86B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: MGM Resorts International is far larger — about 13.6× Sana Biotechnology Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MGM | SANA | |
|---|---|---|
Market Cap | $11.86B | $873.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $5.92 |
52-Week Low | $30.72 | $2.68 |
Enterprise Value | $40.90B | $848.03M |
Dividend Yield | 0.03% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
